Results 191 to 200 of about 4,686,679 (295)
The outcome of experimentally induced inclusion body hepatitis (IBH) by fowl aviadenoviruses (FAdVs) is crucially influenced by the genetic background of the host. [PDF]
Vet Res, 2016 Matos M, Grafl B, Liebhart D, Hess M.
europepmc +1 more source
The International Journal of Health Planning and Management, EarlyView.ABSTRACT Pakistan has hosted Afghan refugees for more than four decades, in one of the world's most protracted displacements of people. Afghan refugees receive health services through United Nations High Commissioner for Refugees (UNHCR) and non‐governmental organisation (NGO) supported programmes alongside public sector facilities at every tier.
Zahid Ali Memon +4 more
wiley +1 more source
New‐Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank
International Journal of Cancer, EarlyView.ABSTRACT The prevalence of type 2 diabetes mellitus (T2DM) is rising rapidly in China and is linked to increased cancer risk, but causality remains unclear due to biases. We examined the causal effect of T2DM on cancer risk using bias‐minimizing methods.
Mengying Wang +9 more
wiley +1 more source
Correction: Pathogenicity and Complete Genome Characterization of Fowl Adenoviruses Isolated from Chickens Associated with Inclusion Body Hepatitis and Hydropericardium Syndrome in China. [PDF]
PLoS One, 2016 Zhao J +4 more
europepmc +1 more source
International Journal of Cancer, EarlyView.ABSTRACT There is no study from Germany on the association between stage of lung cancer (LC) and patient characteristics. We aimed to compare advanced versus non‐advanced LC cases regarding indicators of healthcare utilization. Using claims data covering 20% of the German population, we included LC patients diagnosed between 2013 and 2019.
Josephine Küsel‐Kanbach +2 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt +7 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır +32 more
wiley +1 more source